"Vaccines, Inactivated" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
| Descriptor ID |
D015164
|
| MeSH Number(s) |
D20.215.894.830
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vaccines, Inactivated".
Below are MeSH descriptors whose meaning is more specific than "Vaccines, Inactivated".
This graph shows the total number of publications written about "Vaccines, Inactivated" by people in this website by year, and whether "Vaccines, Inactivated" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 2 | 3 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 3 | 3 |
| 2011 | 1 | 5 | 6 |
| 2012 | 2 | 4 | 6 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 4 | 6 |
| 2016 | 1 | 6 | 7 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 3 | 3 |
| 2019 | 2 | 5 | 7 |
| 2020 | 1 | 5 | 6 |
| 2021 | 1 | 7 | 8 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 4 | 4 |
| 2024 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vaccines, Inactivated" by people in Profiles.
-
Determination of T cell response against XBB variants in adults who received either monovalent wild-type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster. Int J Infect Dis. 2024 Dec; 149:107271.
-
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 Jun 14; 78(6):1757-1768.
-
Cross-Reactive Antibody Responses to Coronaviruses Elicited by SARS-CoV-2 Infection or Vaccination. Influenza Other Respir Viruses. 2024 May; 18(5):e13309.
-
The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial. Clin Infect Dis. 2024 01 25; 78(1):217-226.
-
Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines. Nat Commun. 2024 Jan 04; 15(1):254.
-
Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection. J Infect Dis. 2023 05 29; 227(11):1303-1312.
-
Influenza Vaccine Effectiveness Among Children: 2011-2020. Pediatrics. 2023 04 01; 151(4).
-
Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial. Vaccine. 2023 04 17; 41(16):2716-2722.
-
Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial. Clin Infect Dis. 2023 02 08; 76(3):e1168-e1176.
-
Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine. AIDS. 2022 07 15; 36(9):1255-1264.